Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

DoH group considering consultation on gabapentinoids

By Catherine Reilly - 21st Jan 2022 | 122 views

Pills on blue tableColourful pills

The early warning and emerging trends (EWET) group chaired by the Department of Health is considering a consultation process on controlling pregabalin and gabapentin, which are indicated for the treatment of epilepsy, peripheral and neuropathic pain and generalised anxiety disorder in adults. The EWET is part of the national advisory committee on drugs and alcohol.

A Department spokesperson told the Medical Independent: “The controlling of substances under the Misuse of Drugs Acts 1977-2016 requires a clear evidence base and an analysis of the benefits and risks. If evidence exists to suggest that the scheduling of a substance would reduce its misuse or abuse, a multiple stakeholder approach is required, to include a referral to the European Commission.

“The Department is aware of control measures recently implemented in the UK and Northern Ireland and the data in respect of these measures is still under review by the respective authorities. The early warning and emerging trends group chaired by the Department of Health is considering a consultation process.” In January 2020, National Clinical Lead of the Medicines Management Programme Prof Michael Barry wrote to GPs to “highlight the high level of prescribing of pregabalin and importantly, the risks associated with its use”, including risk of addiction.

Prof Barry’s correspondence included a summary guidance document on appropriate prescribing of pregabalin. He also advised that a prescribing analysis report of pregabalin for patients in their practice would issue in the coming months. In its September 2021 newsletter, the Health Products Regulatory Authority (HPRA) highlighted “that pregabalin has been associated with reports of respiratory depression in the absence of concomitant therapy with opioids or other central nervous system (CNS) depressants, in patients with and without other risk factors for respiratory depression”, as per findings from the pharmacovigilance risk assessment committee of the European Medicines Agency.

The HPRA advised that the product information would be updated and include respiratory depression as an adverse reaction with a frequency of ‘not known’. It was already known that concomitant use of pregabalin with opioids and/or other CNS depressants was associated with reports of respiratory failure, coma and deaths, and this risk was reflected in the product information.

Leave a Reply

Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read